STUDY OF SAFETY AND EFFICACY OF RHGH A/O ROSIGLITAZONE IN HIV

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypothesis: that (1) co-administration of rosiglitazone with recombinant human growth hormone (rhGH) will abrogate the adverse effect of rhGH on insulin sensitivity that may be mediated by increased free fatty acid (FFA) turnover and will have a synergistic effect on reducing visceral adiposity; and (2) the effects of rosiglitazone and rhGH on subcutaneous adipose tissue volume will be determined by their effects on total energy balance. Primary Objectives: to determine (1) the individual and interacting effects of rosiglitazone and rhGH on insulin sensitivity, as assessed by frequently sampled intravenous glucose tolerance test, in HIV-infected subjects with visceral adiposity and insulin resistance; and (2) the individual and interacting effects of rosiglitazone and rhGH on body composition assessed by whole body MRI and dual energy X-ray absorptiometry (DEXA) in HIV-infected subjects with visceral adiposity and insulin resistance.